Article in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Jiakun NieFuzhou Medical College, Nanchang University 9 Donglin Rd. Fuzhou 344000 Jiangxi P. R. China.
Changjie JinSchool of Chemistry and Chemical Engineering, Shanghai Engineering Research Center of Pharmaceutical Intelligent Equipment, Shanghai Frontiers Science Research Center for Druggability of Cardiovascular Non-coding RNA, Institute for Frontier Medical Technology, Shanghai University of Engineering Science 333 Longteng Rd. Shanghai 201620 P. R. China binbin.lou@shgh.cn lewisjia@163.com.
Yonghang LiuSchool of Chemistry and Chemical Engineering, Shanghai Engineering Research Center of Pharmaceutical Intelligent Equipment, Shanghai Frontiers Science Research Center for Druggability of Cardiovascular Non-coding RNA, Institute for Frontier Medical Technology, Shanghai University of Engineering Science 333 Longteng Rd. Shanghai 201620 P. R. China binbin.lou@shgh.cn lewisjia@163.com.
Juan DuSchool of Chemistry and Chemical Engineering, Shanghai Engineering Research Center of Pharmaceutical Intelligent Equipment, Shanghai Frontiers Science Research Center for Druggability of Cardiovascular Non-coding RNA, Institute for Frontier Medical Technology, Shanghai University of Engineering Science 333 Longteng Rd. Shanghai 201620 P. R. China binbin.lou@shgh.cn lewisjia@163.com.
Sihao ChenSchool of Chemistry and Chemical Engineering, Shanghai Engineering Research Center of Pharmaceutical Intelligent Equipment, Shanghai Frontiers Science Research Center for Druggability of Cardiovascular Non-coding RNA, Institute for Frontier Medical Technology, Shanghai University of Engineering Science 333 Longteng Rd. Shanghai 201620 P. R. China binbin.lou@shgh.cn lewisjia@163.com.
Yujia ZhengShanghai Institute of Measurement and Testing Technology 1500 Zhang Heng Rd. Shanghai 201203 P. R. China.
Binbin LouSchool of Chemistry and Chemical Engineering, Shanghai Engineering Research Center of Pharmaceutical Intelligent Equipment, Shanghai Frontiers Science Research Center for Druggability of Cardiovascular Non-coding RNA, Institute for Frontier Medical Technology, Shanghai University of Engineering Science 333 Longteng Rd. Shanghai 201620 P. R. China binbin.lou@shgh.cn lewisjia@163.com.ORCID https://orcid.org/0000-0002-5526-3209
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
The development of injured vascular tissue substitutes with proangiogenic, anti-thrombus, and anti-hyperplasia activity still remains a major challenge in vascular tissue engineering. In this study, we have prepared a series of poly(butylene adipate-
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
PBAT/gelatin hybrid nanofibers based on post-double network bond processing as a promising vascular substitute. · full record | OpenQuestion